Skip to main content

Table 1 Comparison of baseline characteristics in the two groups

From: Comparison of regional citrate anticoagulation and nafamostat mesylate anticoagulation during plasma exchange for children at high bleeding risk: a retrospective study

Indicator

RCA-PE Group

NM-PE Group

P-value

No. of Cases

45

21

 

Age [M (P25, P75), months]

45 (25.5, 85.5)

63.0 (31.0, 103.5)

0.256

Gender (Male/Female, n)

24/21

11/10

0.942

Weight [M (P25, P75), kg]

17.5 (11.7, 21.8)

19.0 (12.7, 27.1)

0.332

PCIS [M (P25, P75), points]

78 (72, 84)

78 (76, 83)

0.777

Mechanical Ventilation [n (%)]

29 (64.4)

13 (61.9)

0.842

Vasopressor Support [n (%)]

16 (35.6)

10 (47.6)

0.350

Platelets [M (P25, P75), x109/L]

40 (27, 71.5)

38 (25, 72.5)

0.967

Hemoglobin [M (P25, P75), g/L]

78 (71.5, 81.0)

77.0 (69.5, 84.5)

0.756

pH [M (P25, P75)]

7.35 (7.24, 7.42)

7.40 (7.24, 7.44)

0.874

HCO3 [M (P25, P75), mmol/L]

20.7 (18.3, 23.6)

18.8(17.2,21.8)

0.164

Ionized Calcium In Vivo (_x ± S, mmol/L)

1.19 ± 0.10

1.22 ± 0.13

0.291

Blood Lactate (_x ± S, mmol/L)

2.1 ± 1.1

2.4 ± 1.5

0.449

Blood Sodium (_x ± S, mmol/L)

133.3 ± 6.1

131.9 ± 5.7

0.408

Blood Potassium [M(P25,P75), mmol/L]

4.4 (3.8, 5.1)

4.2 (3.7, 4.7)

0.606

aPTT [M (P25, P75), s]

58.4 (50.6, 72.3)

65.3 (55.6, 81.0)

0.500

Active Bleeding [n (%)]

3 (6.7)

1 (4.8)

> 0.999

Surgical History within 48 h

3 (6.7)

2 (9.5)

0.650

Etiological Factors [n (%)]

  

0.939

Severe Sepsis

13 (28.9)

4 (19.0)

 

Acute Poisoning

8 (17.8)

5 (23.8)

 

Hemophagocytic Lymphohistiocytosis

14 (31.1)

7 (33.3)

 

Hemolytic Uremic Syndrome

7 (15.6)

3 (14.3)

 

Drug Hypersensitivity Syndrome

2 (4.4)

1 (4.8)

 

Systemic Lupus Erythematosus

1 (2.2)

1 (4.8)

 
  1. PCIS: Pediatric Critical Illness Score; RCA: regional citrate anticoagulation; NM: nafamostat
  2. mesylate; PE: plasma exchange; aPTT: Activated partial thromboplastin time